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We reviewed medical records of 238 hospitalized
patients with Escherichia coli O157:H7 diarrhea to identify
risk factors for progression to diarrhea-associated hemoly-
tic uremic syndrome (HUS). Data indicated that young age,
long duration of diarrhea, elevated leukocyte count, and
proteinuria were associated with HUS.
I
n the United States, Escherichia coli O157:H7 causes
≈73,000 infections and 60 deaths annually (1). Infection
progresses to hemolytic uremic syndrome (HUS) in 2% to
15% of cases (2). In studies of E. coli O157:H7 outbreaks,
female sex, young age, elevated leukocyte count, antimi-
crobial drug use, vomiting, and fever have been reported as
risk factors for HUS (3–11). Previously, a possible associ-
ation between HUS and female sex, young age, and pro-
longed duration of diarrhea was shown in a study that
evaluated the New York state surveillance system for post-
diarrheal HUS (12). This report extends that study to
investigate hospitalized patients with E. coli O157:H7
infection to assess potential risk factors for progression of
infection to HUS by using a case-control study.
The Study
Medical charts of all persons who were hospitalized
and reported with confirmed cases of E. coli O157:H7 to
the New York State Department of Health’s
Communicable Disease Surveillance System (CDSS) in
1998 and 1999 were reviewed according to a standardized
survey form. A HUS case was defined as occurring in a
patient with acute diarrhea who was hospitalized with E.
coli O157:H7 infection and in whom confirmed or proba-
ble postdiarrheal HUS developed. A confirmed HUS case
was defined as occurring in a patient with a clear history of
acute diarrhea who showed the following signs: hemolytic
anemia with microangiopathic changes, renal insufficiency
(creatinine level >1.0 mg/dL in a child <13 years of age or
>1.5 mg/dL in an adult, or >50% increase over baseline),
and thrombocytopenia (platelet count <150,000/µL). A
probable HUS case was defined as occurring in a patient
with acute diarrhea with all the above signs except
microangiopathic changes in the blood smear. Controls
were hospitalized patients with E. coli O157:H7 infection
without HUS. Demographic, clinical, and laboratory char-
acteristics were abstracted from medical charts. Statistical
analysis was performed by using SAS software (SAS
Institute, Cary, NC, USA). A multiple logistic regression
analysis was performed to identify factors associated with
development of HUS. 
In 1998 and 1999, the CDSS received reports of 1,170
cases of E. coli O157: H7 infection. Of these, 255 patients
(21%) were hospitalized and 238 (93%) had medical charts
available for review. Thirty-six (15%) patients were con-
firmed (n = 29) or probable (n = 7) HUS case-patients, and
202 E. coli O157:H7–infected patients without HUS were
identified as controls. The risk of HUS was highest among
children <5 years of age, compared with patients >65 years
(odds ratio [OR] 4.9, 95% confidence interval [CI]
2.2–11.8). Sixty-nine percent of HUS patients were female
compared with 61% of controls (OR 1.5, 95% CI 0.8–3.4).
The hospital stay was significantly longer for HUS patients
than controls (median hospital stay 13 vs. 3 days). Five
HUS patients (14%) died, including 2 children <5 years of
age, compared with 2 controls (1%).
Forty percent of all patients had vomiting, and 85% had
bloody stool. These factors were not significantly different
between patients and controls. Eleven (31%) case-patients
and 78 (38%) controls were treated with antimicrobial
drugs (not significant). Antimicrobial treatment was
reported in 11 patients before the diagnosis of HUS: 6
received antimicrobial drugs primarily for other conditions
(e.g., urinary tract infection, otitis media, venous line sep-
sis), 1 had treatment stopped once E. coli O157:H7 was
diagnosed, and we could not tell whether drug regimens
were completed or discontinued in 4 patients. HUS
patients were more likely than non-HUS controls to have
fever (OR 3.2, 95% CI 1.6–6.5). The duration of diarrhea
before hospitalization was significantly longer for HUS
patients than for non-HUS controls (median 4 vs. 2 days).
Proteinuria and hematuria were observed significantly
more often among the case-patients. Twenty-three (64%)
patients had proteinuria at admission, whereas 37 (18%)
controls were admitted with proteinuria (OR 7.8, 95% CI
3.6–17). Hematuria at admission was reported in 23 (64%)
patients and 57 (28%) controls (OR 4.5, 95% CI 2.1–9.4).
Twenty-nine (81%) HUS patients vs. 90 (44%) controls
had leukocyte counts >13,000/µL (OR 5.2, 95% CI
2.2–12.3) at admission (Table 1). Factors associated with
HUS in univariate analysis (age <5 years, outbreak case,
fever, hematuria, proteinuria, leukocytosis at admission,
and duration of diarrhea before hospitalization >3 days)
were included in the multivariate analysis. The following
variables were associated with HUS development in the
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1.9–24.1), duration of diarrhea before hospitalization >3
days (OR 6.2, 95% CI 2.2–17.4), age <5 years (OR 5.9,
95% CI 1.9–17.6), and leukocyte count >13,000/mL (OR
4.4, 95% CI 1.6–12.6). Factors such as outbreak involve-
ment, hematuria and fever were not associated with HUS
development (Table 2).
Conclusions 
This study provides additional information on potential
risk factors for progression of E. coli O157:H7 infection to
HUS, but unlike other studies, this study used hospitalized
rather than outpatient controls. Our data confirmed previ-
ous differences in risk for HUS development by age group
(3–5). Women and girls have been reported to be at
increased risk for HUS development in several studies
(10,11), but our study showed no significant increased risk.
Several studies have suggested that administration of
antimicrobial agents increases risk for HUS development
(5,6,9,13), but no significant relationship was observed
between HUS and the use of antimicrobial drugs in our
sample. 
Although reports (5,7) have demonstrated a higher inci-
dence of HUS among patients with bloody diarrhea, fever,
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nificant association between these characteristics and
HUS. Since only hospitalized patients with severe diarrhea
were studied, some symptoms (bloody stool, fever, or
vomiting) might have been reported more often than in the
general population with E. coli O157:H7 infection. As a
result, some significant associations might have been
missed. Buteau et al. (14) reported that a diarrheal pro-
drome <3 days is an independent predictor of HUS devel-
opment in children with E. coli O157:H7 infection;
however, our study suggested that prolonged diarrhea (>3
days) may increase the risk of HUS.
Our analysis was consistent with results of other stud-
ies that found patients with elevated leukocyte counts to be
at higher risk for developing HUS (5–8,14). Patients with
leukocytes >13,000/µL at admission in our study had 5
times the risk of HUS. Protein and occult blood in urine
were described as risk factors for HUS in a study in Japan
(15). In the current study, proteinuria at admission was also
a risk factor for HUS. However, HUS had already devel-
oped in most of these patients by the time of hospitaliza-
tion, and we could not determine whether these factors
preceded HUS development.
In summary, patients hospitalized for E. coli O157:H7
infection, those <5 years of age with >3 days of diarrhea,
leukocytes >13,000/µL, and proteinuria should be moni-
tored closely for further complications. Nine (25%) of the
HUS patients had 4 risk factors, 11 (31%) patients had 3
risk factors, and 10 (28%) had 2 risk factors. In comparison,
none of the controls had these 4 risk factors, 4 (2%) had 3
risk factors, and 47 (23%) had 2 risk factors. Identifying
potential risk factors may allow clinicians to develop treat-
ment interventions to prevent progression to HUS.
Ms Tserenpuntsag is a DrPH student majoring in epidemiol-
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